PRE-CONFERENCE WORKSHOPS: Tuesday, March 13, 2012

Pre-Conference Workshop Registration Fee

	Received on or BeforeFebruary 16, 2012		Received AfterFebruary 16, 2012
Half Day	$75		$95
Full Day	$125		$145

Pre-Conference Workshop 1
8:30 a.m.-12:00 noon
Dissemination of Treatment Research Findings into Clinical Practice: A Joint SRNT/ATTUD Conference
Presenters: John Hughes, M.D. and Glen Morgan, Ph.D.

A major goal of treatment research is to provide evidence-based treatments to be used in real-world setting. This requires not only efficacy studies but also dissemination and effectiveness studies. The purpose of this pre-conference is to provide examples of such studies. The pre-conference is organized by a collaboration between the SRNT Treatment Network and the Association for the Treatment of Tobacco Use and Dependence (www.attud.org). The latter is a professional organization of Tobacco Treatment Specialist (TTSs) that aims to promote evidence-based treatments for tobacco dependence. Monica Sutton PhD (Univ MS) will introduce and Jonathan Foulds, PhD (Penn State) will moderate the program. John Hughes, MD (Univ VT) will first briefly describe the "evidence-based medicine" approach that ATTUD advocates. Matthew Bars, MS, CTTS (Fire Dept of NY) will describe methods used by FDNY that decreased smoking prevalence from 27% immediately after 9/11 to 7% now. Thomas Payne, PhD (Univ MS) will describe the outcomes of a statewide network of intensive treatment programs. Nancy Rigotti, MD (Harvard) will review proven cessation programs in hospital settings and discuss methods to implement such programs. Christine Sheffer, PhD (Univ AK for Med Sciences) will describe differences in smokers who chose quitline vs in person treatments. Christi Patten, PhD (Mayo Clinic) will discuss research on helping significant others prompt smokers to quit and how this might currently be implemented. Matthew Carpenter, PhD (Med Univ of SC) will review clinical methods to motivate smokers to make a quit attempt and their applicability across settings. Glenn Morgan PhD (NCI) will make closing remarks. The introduction and presentations will require about 150 min and the break 15 min. If the half-day conference is to last 4 hours, this would leave about 65 min for audience participation.

Pre-Conference Workshop 2
8:30 a.m.-12:00 noon
The Smoking Cessation and Reduction In Pregnancy Treatment (SCRIPT) Program: Translating Science to Prenatal Care Programs and Professional Practices
Presenter: Richard Windsor, Ph.D., M.P.H.

Smoking is one of the most important risk factors for fetal, infant and maternal morbidity and mortality. The "Smoking Cessation and Reduction In Pregnancy Treatment (SCRIPT) Program" was designed to be an integrated, component of a patient education program. The "effectiveness" of SCRIPT delivered as part of routine prenatal care by regular providers has been rigorously evaluated (1982-2011). Meta-analyses by the US-DHHS-Agency for HealthCare Research and Quality (AHRQ), the Cochrane Collaboration Review (2007), and multiple evaluation studies in five countries of the acceptability, effectiveness, and cost effectiveness of methods for pregnant smokers have defined The Clinical Practice Guidelines for Treating Tobacco Use and Dependence (AHRQ, 2000 + 2008). Valid and reliable methods exist: 1) to assist patients to quit or significantly reduce smoking, 2) to measure their levels of daily tobacco exposure and 3) to evaluate the quality, process, impact and cost of delivering and adopting SCRIPT Procedures for systems of care and practitioners. The purpose of this Workshop is to assist participants in 1) describing current trends and methods to assess tobacco exposure during pregnancy; 2) identifying best practice measurement methods for routine assessment; 3) identifying "Best Practice" counseling methods for pregnant smokers; 4) defining the evidenced-based SCRIPT intervention to assist pregnant smokers to quit smoking; 5) defining Process, Impact and Cost Evaluation methods for the SCRIPT intervention; and 6) identifying methods to integrate SCRIPT interventions in OB/Prenatal Care systems and practices.

Pre-Conference Workshop 3
8:30 a.m.-4:30 p.m. Cholinergic Regulation of Addiction and Disease: Understanding Mechanisms and Identifying Novel Therapeutic Targets
Workshop Coordinators: Mariella De Biasi, Ph.D. and Darlene Brunzell, Ph.D.

The cholinergic system supports many brain functions including learning and memory, attention, affect, motivation, reward and aversion. The nicotine contained in tobacco effectively hijacks the cholinergic system leading to changes in neural plasticity that support addiction and lead to changes in mood and cognition. These system neuroscience talks will address the diverse classes of nicotinic receptor subtypes that support various behaviors relevant to drug dependence, neurodegenerative disorders and mental illness. Speakers for this full-day workshop include John Dani, Robin Lester, Rory McQuiston, Kelly Dineley, Adriana Alcantara, Christie Fowler, Raad Nashmi and Roger Papke. Ample time is provided for audience discussion in order to stimulate the exchange of scientific ideas for the translation of basic science research. This workshop is intended for individuals who are interested in neurochemical, neuroanatomical, physiological and molecular mechanisms of behavior with the goal of identifying novel therapeutic targets for tobacco addiction and related illness.

Pre-Conference Workshop 4
8:30 a.m.-4:30 p.m.
New Methods for Advancing Research on Tobacco Dependence
Tobacco Researchers: Lisa Dierker, Ph.D., Wesleyan; Danielle McCarthy, Ph.D., Rutgers; Robin Mermelstein, Ph.D., University of Illinois, Chicago; Tom Piasecki, Ph.D., University of Missouri; Megan Piper, Ph.D., University of Wisconsin; Saul Shiffman, Ph.D., University of Pittsburgh.

Quantitative Methods Researchers: Don Hedeker, Ph.D., University of Illinois, Chicago; Stephanie Lanza, Ph.D., Penn State; Runze Li, Ph.D., Penn State; Daniel Rivera, Ph.D., Arizona State.

Discussants: Elizabeth Ginexi, Ph.D., National Cancer Institute and Linda M. Collins, Ph.D., Penn State.

The primary goal of this workshop is to increase uptake of new methods for collection and analysis of data from tobacco studies, in order to advance our understanding of complex pre- and post-quit processes, effects of treatment on those processes, and the role of milestones (such as lapse and relapse) in the process of quitting. Speakers will describe challenges and best practices related to studying smoking behavior, in particular smoking cessation, which often involves the collection of intensive longitudinal data or ecological momentary assessment (EMA) data and random assignment to treatment conditions. Open questions in tobacco research that require new methods will be discussed. The time-varying effect model and related methods for addressing new questions using intensive longitudinal data and EMA data will be introduced. To achieve the primary goal, the agenda will include substantive and methodological talks, as well as an invited poster session during which early-career scientists will present their research. The target audience is researchers who have, or plan to collect, intensive longitudinal behavioral data or EMA data related to tobacco dependence. Presenters include renowned tobacco researchers (Lisa Dierker, Ph.D., Wesleyan; Danielle McCarthy, Ph.D., Rutgers; Robin Mermelstein, Ph.D., University of Illinois, Chicago; Tom Piasecki, Ph.D., University of Missouri; Megan Piper, Ph.D., University of Wisconsin; Saul Shiffman, Ph.D., University of Pittsburgh) and researchers focused on new quantitative methods (Don Hedeker, Ph.D., University of Illinois, Chicago; Stephanie Lanza, Ph.D., Penn State; Runze Li, Ph.D., Penn State; Daniel Rivera, Ph.D., Arizona State). Discussion will be provided by Elizabeth Ginexi, Ph.D., National Cancer Institute and Linda M. Collins, Ph.D., Penn State. The workshop is organized by Stephanie Lanza, Ph.D., Research Associate Professor, Penn State and Scientific Director of The Methodology Center and Megan Piper, Ph.D., Assistant Professor, University of Wisconsin and Lead Researcher, Center for Tobacco Research and Intervention.

Pre-Conference Workshop 5
8:30 a.m.-4:30 p.m.
Biomarker Development for Nicotine Dependence
Chair(s): Jed Rose, Ph.D. and Caryn Lerman, Ph.D.

Presenters:

• Pharmacogenomics - George Uhl, M.D., Ph.D., Sean P. David, M.D., S.M., D.Phil
• Drug Metabolism - Caryn Lerman, Ph.D., Rachel Tyndale, M.Sc, Ph.D.
• CNS imaging - Elliott Stein Ph.D., F. Joe McClernon, Ph.D.
• Biostatistician(s) - Chuck Green, Ph.D., David Conti, Ph.D.

Discussant(s):

• FDA panelist(s) TBD (Bob Rappaport's Division at CDER)
• Paul Kenny, Ph.D., discuss preclinical / translational biomarkers potential

In 2009, 46.6 million adults were regular smokers. Although approximately 70% of smokers wanted to quit, only a modest number of smokers are able to remain abstinent without behavioral therapy, pharmacotherapy or both. - As a result, nearly 440,000 smokers die each year in the US alone. There are three FDA-approved first-line medications for tobacco dependence, yet each has limited efficacy. One of the most significant impediments slowing drug development is the lack of quantitative biomarkers that can more hastily speed or eliminate an experimental pharmacotherapy from further development. If a biomarker could be identified, reliably measured and consistently analyzed, it could be used to predict quitting success, to personalize therapy delivery, and to optimize the process of development of new treatment modalities. This symposium will review existing evidence pertaining to pharmacogenomic, drug metabolism, and neuroimaging biomarkers. Drs. Uhl and David will discuss human GWAS data. Drs. Lerman and Tyndale will then discuss human nicotine metabolism, genotype-metabolism relationships, and how, metabolism markers could be used to tailor a therapeutic strategy for different populations of smokers, and to develop novel treatments. Drs. Stein and McClernon will subsequently discuss functional (MRI) and diffusion tensor imaging (DTI) neuroimaging data that identify neural signatures of activation and functional connectivity that might be used to further stratify smokers for more effective drug development and delivery. Drs. Green and Conti will then present the potential to algorthimically combine these measures into one collective personal risk 'score'. This one-day session will be chaired by Drs. Jed Rose and Caryn Lerman. The incorporation of an FDA-recognized (set of) biomarker(s) for drug development would represent a paradigm shift in how the safety and efficacy of novel medications are ultimately evaluated in early Phase I and II clinical trials, a position where nearly 67% of all clinical drug development fails.

Pre-Conference Workshop 6
1:00 p.m.-4:30 p.m.
Advancing the Science and Practice of Behavioral Support for Smoking Cessation
Presenters: Robert West, Ph.D. and Susan Michie, BA, MPhil, DPhil, CPsychol, AcSS, FEHPsS, FBPsS

Behavioural support can increase success at quitting smoking whether delivered face to face individually or in groups, by telephone, text messaging, or internet. The NNT is typically 20-30. Some specific components have been evaluated such as CBT for depression, advice on exercise, use of 'buddy' systems etc. but the key active ingredients are largely unexplored and there is no clear evidence of progression in achieving improved effectiveness. Part of the reason for this is a lack of adequate methodological tools. Several advances in recent years provide opportunities to advance this area of study. These include:

1. The development of systems for specifying the behaviour change techniques (BCTs) used in behavioural support and linking these to underlying theory
2. Improved study designs that permit evaluation of incremental improvements in effectiveness of interventions as a function of components that may be added, deleted or modified
3. Technological developments that allow delivery and rapid innovation of BCTs through a range of modalities, e.g. internet, text messaging
4. Huge increase in reach of behavioural support through national and regional programmes (e.g. the English Stop-Smoking Services) and new technologies, allowing creation of large datasets
5. Advances in statistical techniques for dealing with n-of-one, within-subject, time series and multi-level designs

This workshop will aim to review the state of the art with regard to methodological opportunities for advancing behavioural support and to begin the process of developing and co-ordinating a long-term strategy for exploiting these. The ultimate goal will be to achieve a step-change in the effectiveness of behavioural support.

Pre-Conference Workshop 7
1:00 p.m.-4:30 p.m.
Turning Research Into Action
Presenter: Mike Freiberg

This workshop will provide a "how to" on drafting effective tobacco control policies, with a focus on three specific tobacco control topics: 1) regulatory gaps related to non-cigarette tobacco products; 2) secondhand smoke infiltration in public housing, common interest communities (condominiums), and other types of multi-unit housing; and 3) drafting effective policies, using as a case study Minnesota's Tobacco Modernization Act as, a law which expanded Minnesota's tobacco control laws to make them more inclusive of novel tobacco and nicotine products. This workshop will highlight collaborative research between ClearWay Minnesota^SM and the Public Health Law Center, focusing on how the conclusions from these projects can be turned into effective policies. The workshop will provide valuable lessons for researchers, whose research may cause them to see the need for dramatic policy changes. Although these changes may seem obvious to the Principal Investigators of a study, they will not be effectively realized unless they are put into strong policy language that will withstand legal challenges. This workshop will teach participants how to do this. It will be led by the Principal Investigators on ClearWay's two most recent grants to the Public Health Law Center: Mike Freiberg, J.D., and Warren Ortland, J.D. Mr. Freiberg and Mr. Ortland are both Staff Attorneys with the Public Health Law Center.